



Medi-Cal Rx

Medi-Cal Rx Monthly Bulletin

November 1, 2025

Medi-Cal Rx has implemented or scheduled the following updates. Stay up to date with all that is happening at Medi-Cal Rx by visiting the [Bulletins & News](#) page and signing up for the [Medi-Cal Rx Subscription Service](#) to receive notification of future publications.

1. [Updates to the Medi-Cal Rx Contract Drugs List](#)
2. [Updates to the Medi-Cal Rx Provider Manual](#)
3. [Onsite and Desk Audit Process, Effective November 17, 2025](#)
4. [Upcoming Change in Coverage for Dental Fluoride Products](#)
5. [Reminder: Pyzchiva®\(ustekinumab-ttwe\) Added to the Medi-Cal Rx Contract Drugs List](#)

1. Updates to the Medi-Cal Rx Contract Drugs List

The following updates have been made to the [Medi-Cal Rx Contract Drugs List](#) (CDL).

Drug Name	Description
Azelaic Acid	Added to the CDL.
Ceritinib	Prior authorization (PA) required.
Dabrafenib	PA required.
Ibrutinib	PA required.
Lapatinib	PA required.
Nelarabine	Additional labeler restriction (LR) (66758) added.
Ofatumumab	PA required.
Pazopanib Hydrochloride	PA required.
Pembrolizumab and Berahyaluronidase alfa-pmph	Added to the CDL with LR.
Risankizumab-rzaa	LR added.
Sacubitril-Valsartan	Added to the CDL.
Ticagrelor	Effective December 1, 2025: Removed LR for 90 mg tablets.
Trametinib	PA required.

2. Updates to the Medi-Cal Rx Provider Manual

The following updates/additions have been made to the [Medi-Cal Rx Provider Manual](#).

Section	Update Description
<i>Section 3.6 – Medi-Cal Rx Web Portal</i>	Refined and added language about what resources can be found on the Medi-Cal Rx Web Portal.
<i>Section 3.6.1 – Medi-Cal Rx Provider Portal</i>	Refined language defining the unsecured and secured portals.
<i>Section 3.6.1.1 – Unsecured Provider Portal</i>	Refined and added language about what resources can be found on the Medi-Cal Rx Provider Portal.
<i>Section 15.8 – Physician Administered Drugs (PADs)</i>	Refined language defining physician administered drugs (PADs).

Section	Update Description
<i>Section 15.8.1 – Coverage</i>	- Refined language regarding PADs coverage. - Removed the <i>Medi-Cal Rx Pharmacy Reimbursable Physician Administered Drugs</i> link and added the <i>Medi-Cal Rx Approved NDC List</i> link.
<i>Section 15.8.2 – Reject Code 816</i>	- Updated the Reject Code 816 supplemental message. - Updated PADs policy information regarding coverage exceptions and PA request requirements.
<i>Section 15.8.3 – MCP Obligation</i>	- Refined language regarding PADs policy information. - Removed the <i>Medi-Cal Rx Pharmacy Reimbursable Physician Administered Drugs</i> link and added the <i>Medi-Cal Rx Approved NDC List</i> link.

3. Onsite and Desk Audit Process, Effective November 17, 2025

To continue enhancing the integrity of Medi-Cal Rx, the Department of Health Care Services (DHCS) has contracted with Prime Therapeutics State Government Solutions LLC (Prime) to conduct audits of pharmacies enrolled in Medi-Cal. Effective November 17, 2025, in addition to audits performed by DHCS' Audits & Investigations (A&I) Division, Prime will begin conducting onsite and desk audits to regularly monitor compliance with relevant Medicaid state and federal statutes, regulations, policies, terms of applicable provider agreements, lists published to the [Contract Drugs & Covered Products Lists](#) page on the [Medi-Cal Rx Web Portal](#), and policy outlined in the [Medi-Cal Rx Provider Manual](#). Pharmacy providers will receive a letter if one or more of their claims has been selected for review with instructions about what documentation the pharmacy provider must submit along with the due date.

Pharmacies have the right to appeal their audit findings per *California Code of Regulations* (CCR), Title 22, Section 51022 and *Welfare and Institutions Code* (W&I Code), Section 14171.

The *Medi-Cal Rx Provider Manual* will be updated to include more details about the pharmacy audit process on December 1, 2025.

4. Upcoming Change in Coverage for Dental Fluoride Products

Effective December 1, 2025, dental fluoride products will no longer be covered under Medi-Cal Rx. Medi-Cal Rx may consider claims for these products on a case-by-case basis for Medi-Cal members with additional coverage under Early and Periodic Screening, Diagnostic, and Treatment (EPSDT), provided that a PA request is submitted along with documentation supporting medical necessity.

5. Reminder: Pyzchiva®(ustekinumab-ttwe) Added to the Medi-Cal Rx Contract Drugs List

Pyzchiva® (ustekinumab-ttwe) injection and vials, an interchangeable biosimilar to Stelara® (ustekinumab), were added to the [CDL](#) with Code I restrictions on September 1, 2025, and October 1, 2025, respectively. These products will not require a PA request when Code I restrictions are met.

Providers are reminded that Medi-Cal Rx requires the use of least costly drug/products including, but not limited to, drugs/products listed on the [Contract Drugs & Covered Products Lists](#) page. Consideration of a non-CDL listed drug/product requiring a PA request will be based on medical necessity.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.